CompletedPhase 2/3

The Role of OmniLenz® in the Treatment of Small Corneal Perforations Secondary to Exposure Keratitis in ICU Patients

Kuwait5 participantsStarted 2022-04-10

Plain-language summary

Case series of 5 ICU patients in Farwaniya Hospital who developed exposure keratitis and a subsequent small corneal perforation between April 2022 and April 2024. The investigators highlight the non-surgical role of OmniLenz® in the treatment of small corneal perforations secondary to exposure keratitis. The inclusion criteria were corneal perforation less than 1mm in size, positive culture \& sensitivity results and showing initial improvement on topical antibiotic eye drops.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion/Exclusion Criteria: * Patients with small corneal perforations measuring \< 1 mm in diameter. Those with larger perforations (\>1mm) were excluded. * Patients with conclusive results of keratitis (confirmed via culture and sensitivity scraping) AND showing improved keratitis following antibiotic treatment. Those with no confirmed keratitis through C\&S or with inconclusive scraping results were excluded. * No age or gender restrictions were applied.

What they're measuring

Size of corneal perforation

Timeframe: one week

Trial details

NCT IDNCT06539663

SponsorFarwaniya Hospital

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2024-02-10

View on ClinicalTrials.gov More Corneal Perforation trials